JP2017526625A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526625A5
JP2017526625A5 JP2016574456A JP2016574456A JP2017526625A5 JP 2017526625 A5 JP2017526625 A5 JP 2017526625A5 JP 2016574456 A JP2016574456 A JP 2016574456A JP 2016574456 A JP2016574456 A JP 2016574456A JP 2017526625 A5 JP2017526625 A5 JP 2017526625A5
Authority
JP
Japan
Prior art keywords
nucleic acid
region
polypeptide
protein dimer
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016574456A
Other languages
English (en)
Japanese (ja)
Other versions
JP6687548B2 (ja
JP2017526625A (ja
Filing date
Publication date
Priority claimed from GBGB1411506.7A external-priority patent/GB201411506D0/en
Application filed filed Critical
Publication of JP2017526625A publication Critical patent/JP2017526625A/ja
Publication of JP2017526625A5 publication Critical patent/JP2017526625A5/ja
Application granted granted Critical
Publication of JP6687548B2 publication Critical patent/JP6687548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016574456A 2014-06-27 2015-06-26 変性された潜在関連蛋白質構成物 Expired - Fee Related JP6687548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411506.7A GB201411506D0 (en) 2014-06-27 2014-06-27 Modified latency associated protein construct
GB1411506.7 2014-06-27
PCT/GB2015/051877 WO2015198072A1 (en) 2014-06-27 2015-06-26 Modified latency associated protein construct

Publications (3)

Publication Number Publication Date
JP2017526625A JP2017526625A (ja) 2017-09-14
JP2017526625A5 true JP2017526625A5 (enExample) 2018-06-28
JP6687548B2 JP6687548B2 (ja) 2020-04-22

Family

ID=51410274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574456A Expired - Fee Related JP6687548B2 (ja) 2014-06-27 2015-06-26 変性された潜在関連蛋白質構成物

Country Status (5)

Country Link
US (2) US10435451B2 (enExample)
EP (1) EP3160992B1 (enExample)
JP (1) JP6687548B2 (enExample)
GB (1) GB201411506D0 (enExample)
WO (1) WO2015198072A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
KR20220167295A (ko) * 2020-04-10 2022-12-20 싸이톰스 테라퓨틱스, 인크. 활성화가능한 사이토카인 작제물과 관련된 조성물 및 방법
JP2023534300A (ja) * 2020-07-17 2023-08-08 ジ ユニバーシティ オブ ウェスタン オーストラリア 癌の処置のための組成物および方法
US11667687B2 (en) 2021-03-16 2023-06-06 Cytomx Therapeutics, Inc. Masked activatable interferon constructs
CN120603603A (zh) * 2023-01-12 2025-09-05 瑞泽恩制药公司 用于靶向递送TGFβ的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US20030022316A1 (en) * 2001-01-24 2003-01-30 Fox Brian A. CUB domain protein zcub3 and materials and methods for making it
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein

Similar Documents

Publication Publication Date Title
JP2017526625A5 (enExample)
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
JP2014503198A5 (enExample)
JP7536294B2 (ja) 抗体のFc領域改変体
IL261432B1 (en) Induced binding proteins and methods of use
JP2012505902A5 (enExample)
JP2016526909A5 (enExample)
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
JP2017140051A5 (enExample)
HRP20231118T1 (hr) Sintetizirani polipeptidi koji vežu transferinske receptore
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2005024044A3 (en) Method for the production of fusion proteins in transgenic mammal milk
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
JP2014510518A5 (enExample)
CN105658228B (zh) 结合人类补体c5的稳定多肽
JP2015504052A5 (enExample)
WO2007126798A3 (en) Regulated expression of recombinant proteins from adeno-associated viral vectors
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
JP2018512124A5 (enExample)
JP2014510519A5 (enExample)
ATE517118T1 (de) Bis-met-histone
CA3195315A1 (en) Compositions and methods for selective depletion of target molecules
JP2010504336A5 (enExample)